Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.
There are few situations in which the standard of care is so clear-cut as to preclude physician judgment. Assessing the degree of need (not just the standard of care) when asking a patient to spend money requires judgment.
Physician employment adds a practice management stakeholder to the patient-physician encounter, a stakeholder whose financial interests differ from those of physicians in solo or group practice.
The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015;17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.
The casebook developed by the Bander Center for Medical Business Ethics provides a comprehensive instrument for teaching medical business ethics decision making by exploring the effects of relevant variables on medical practice and research and reflecting on the values and motives that influence the behavior of health care professionals.
AMA J Ethics. 2015;17(8):744-749. doi:
10.1001/journalofethics.2015.17.8.medu1-1508.